Cybrexa Therapeutics, a New Haven, CT-based biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, completed a $13.4m Series B1 financing.
Backers in the round, which brings total capital raised to date to $21.1m, included CT Innovations, HighCape Capital Special Opportunities Fund, and Cycle Venture Partners.
The company intends to use the funds to advance its first clinical candidate CBX-11 (alphalexTM-rucaparib) into clinical development and to progress additional programs in its preclinical pipeline.
Led by Per Hellsund, President & CEO, Cybrexa is a biotechnology company dedicated to developing an entirely new class of cancer therapies using its alphalex™ platform to deliver anti-cancer agents directly into tumor cells.
The company’s lead candidate, CBX-11 (alphalex™-rucaparib), is in preclinical development with advancing plans to initiate clinical development by 1Q 2020.